Cargando…
Field Validation of a Rapid Recombinase Aided Amplification Assay for SARS-CoV-2 RNA at Customs — Zhejiang Province, China, January 2021
INTRODUCTION: The best approach to preventing the importation of coronavirus disease 2019 (COVID-19) is enhancing the detection capacity at customs. The rapid detection is of utmost importance and therefore highly demanded. METHODS: We conducted a field validation study of a duplex real-time reverse...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598545/ https://www.ncbi.nlm.nih.gov/pubmed/34804630 http://dx.doi.org/10.46234/ccdcw2021.236 |
_version_ | 1784600826745978880 |
---|---|
author | Shen, Xinxin Wang, Jinrong Li, Jingyi He, Anna Liu, Hong Ma, Xuejun |
author_facet | Shen, Xinxin Wang, Jinrong Li, Jingyi He, Anna Liu, Hong Ma, Xuejun |
author_sort | Shen, Xinxin |
collection | PubMed |
description | INTRODUCTION: The best approach to preventing the importation of coronavirus disease 2019 (COVID-19) is enhancing the detection capacity at customs. The rapid detection is of utmost importance and therefore highly demanded. METHODS: We conducted a field validation study of a duplex real-time reverse transcription recombinase-aided amplification (RT-RAA) assay in Zhoushan and Hangzhou customs, in Zhejiang Province, China. The reverse transcriptase polymerase chain reaction (RT-PCR) assay kit routinely used at customs was used in parallel, and the duration the two methods took to complete a specific number of samples was compared. RESULTS: Among 506 samples collected, RT-RAA results were consistent with the RT-PCR results. The sensitivity and specificity were 100%, the total coincidence rate was 100%, and the Kappa value was 1 (P<0.05) for both methods. The RT-RAA kit took a significantly shorter time in testing the 20–200 samples than the RT-PCR kit. DISCUSSION: The RT-RAA detection method is more efficient and suitable for use at customs than RT-PCR assay to realize rapid customs clearance of 200 or fewer samples. |
format | Online Article Text |
id | pubmed-8598545 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-85985452021-11-19 Field Validation of a Rapid Recombinase Aided Amplification Assay for SARS-CoV-2 RNA at Customs — Zhejiang Province, China, January 2021 Shen, Xinxin Wang, Jinrong Li, Jingyi He, Anna Liu, Hong Ma, Xuejun China CDC Wkly Methods and Applications INTRODUCTION: The best approach to preventing the importation of coronavirus disease 2019 (COVID-19) is enhancing the detection capacity at customs. The rapid detection is of utmost importance and therefore highly demanded. METHODS: We conducted a field validation study of a duplex real-time reverse transcription recombinase-aided amplification (RT-RAA) assay in Zhoushan and Hangzhou customs, in Zhejiang Province, China. The reverse transcriptase polymerase chain reaction (RT-PCR) assay kit routinely used at customs was used in parallel, and the duration the two methods took to complete a specific number of samples was compared. RESULTS: Among 506 samples collected, RT-RAA results were consistent with the RT-PCR results. The sensitivity and specificity were 100%, the total coincidence rate was 100%, and the Kappa value was 1 (P<0.05) for both methods. The RT-RAA kit took a significantly shorter time in testing the 20–200 samples than the RT-PCR kit. DISCUSSION: The RT-RAA detection method is more efficient and suitable for use at customs than RT-PCR assay to realize rapid customs clearance of 200 or fewer samples. Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2021-11-12 /pmc/articles/PMC8598545/ /pubmed/34804630 http://dx.doi.org/10.46234/ccdcw2021.236 Text en Copyright and License information: Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2021 https://creativecommons.org/licenses/by-nc-sa/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ (https://creativecommons.org/licenses/by-nc-sa/4.0/) |
spellingShingle | Methods and Applications Shen, Xinxin Wang, Jinrong Li, Jingyi He, Anna Liu, Hong Ma, Xuejun Field Validation of a Rapid Recombinase Aided Amplification Assay for SARS-CoV-2 RNA at Customs — Zhejiang Province, China, January 2021 |
title | Field Validation of a Rapid Recombinase Aided Amplification Assay for SARS-CoV-2 RNA at Customs — Zhejiang Province, China, January 2021 |
title_full | Field Validation of a Rapid Recombinase Aided Amplification Assay for SARS-CoV-2 RNA at Customs — Zhejiang Province, China, January 2021 |
title_fullStr | Field Validation of a Rapid Recombinase Aided Amplification Assay for SARS-CoV-2 RNA at Customs — Zhejiang Province, China, January 2021 |
title_full_unstemmed | Field Validation of a Rapid Recombinase Aided Amplification Assay for SARS-CoV-2 RNA at Customs — Zhejiang Province, China, January 2021 |
title_short | Field Validation of a Rapid Recombinase Aided Amplification Assay for SARS-CoV-2 RNA at Customs — Zhejiang Province, China, January 2021 |
title_sort | field validation of a rapid recombinase aided amplification assay for sars-cov-2 rna at customs — zhejiang province, china, january 2021 |
topic | Methods and Applications |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598545/ https://www.ncbi.nlm.nih.gov/pubmed/34804630 http://dx.doi.org/10.46234/ccdcw2021.236 |
work_keys_str_mv | AT shenxinxin fieldvalidationofarapidrecombinaseaidedamplificationassayforsarscov2rnaatcustomszhejiangprovincechinajanuary2021 AT wangjinrong fieldvalidationofarapidrecombinaseaidedamplificationassayforsarscov2rnaatcustomszhejiangprovincechinajanuary2021 AT lijingyi fieldvalidationofarapidrecombinaseaidedamplificationassayforsarscov2rnaatcustomszhejiangprovincechinajanuary2021 AT heanna fieldvalidationofarapidrecombinaseaidedamplificationassayforsarscov2rnaatcustomszhejiangprovincechinajanuary2021 AT liuhong fieldvalidationofarapidrecombinaseaidedamplificationassayforsarscov2rnaatcustomszhejiangprovincechinajanuary2021 AT maxuejun fieldvalidationofarapidrecombinaseaidedamplificationassayforsarscov2rnaatcustomszhejiangprovincechinajanuary2021 |